MAPK3 and lip and oral cavity carcinoma: To determine whether the treatment of HO‐3867 could activate MAPK signalling in human oral cancer cells, we detected the phosphorylated levels of ERK1/2, JNK1/2 and p38 in human oral cancer cells SCC‐9 and HSC‐3 cells using immune blot.